Vaxcyte Targets VAX-31 License Application in 2028 After Meeting Primary Endpoints

Key Facts
Vaxcyte said its investigational vaccine VAX-31 met all prespecified primary endpoints in the pivotal Phase 3 OPUS-1 trial in adults, a result supporting the company’s path toward a biologics license application in the first half of 2028. The trial enrolled 4,047 U.S. adults who had not previously been vaccinated against pneumococcal disease. The company said participants included 3,572 people aged 50 and older and 475 people aged 18 to 49. In the older group, the vaccine met the prespecified co-primary immunogenicity endpoints. The results remain one step in a development program requiring additional data and a manufacturing consistency study before submission.
In the prespecified comparative analysis, VAX-31 met the noninferiority criterion for 20 of 20 serotypes shared with PCV20 and 17 of 19 serotypes shared with PCV21. The vaccine did not meet the more stringent prespecified criterion for serotypes 3 and 12F compared with PCV21. Among participants aged 50 and older, the company said all 28 serotypes shared with PCV20 and/or PCV21 met the noninferiority criterion, while the three vaccine-unique serotypes and the cross-reactive serotype 20B met the superiority criterion. These results show the immunogenicity comparison across the serotypes tested in the study. Vaxcyte also said that meeting the primary endpoints does not eliminate the need to complete readouts from the other trials.
OPUS-1 tested the vaccine in participants at multiple U.S. sites, with those aged 50 and older randomly assigned in a 1:1:1 ratio to receive a single dose of VAX-31, PCV20 or PCV21. Participants aged 18 to 49 were assigned in a 3:1 ratio between VAX-31 and PCV20. The company said the vaccine was well tolerated and had a safety profile similar to the two comparator vaccines across all ages studied. It added that no serious adverse events were attributed to the study vaccines. According to the company, VAX-31 is designed to cover about 95% of invasive pneumococcal disease cases and 88% of pneumococcal pneumonia cases among U.S. adults aged 50 and older; these are design estimates, not clinical efficacy results.
The company expects to announce safety, tolerability and immunogenicity data from the Phase 3 OPUS-2 and OPUS-3 studies in the first half of 2027; enrollment in both studies is complete. The results are part of the evidence Vaxcyte said it will assemble before submitting the license application. In parallel, the company expects initial safety, tolerability and immunogenicity data from its Phase 2 study of the vaccine in infants by the end of the first half of 2027. The study includes the primary vaccination series and booster dose, and results for the two cohorts may be released sequentially or at the same time. This means the infant program remains at an earlier stage than the adult program.
Vaxcyte is targeting a biologics license application, or BLA, in the first half of 2028, after the OPUS-2 and OPUS-3 data and completion of the manufacturing consistency study, which the company described as the final study required for the application. The company said OPUS-1 results will be the cornerstone of the planned application, which will be reviewed by the U.S. Food and Drug Administration. In May 2025, the FDA expanded the vaccine’s breakthrough therapy designation to include prevention of pneumococcal pneumonia, in addition to prevention of invasive disease in adults. The company estimates pneumococcal pneumonia causes about 225,000 hospitalizations among adults in the United States annually. Regulatory approval remains subject to review of the application and fulfillment of its requirements.
At the Jefferies Healthcare Conference in London on November 18, 2026, Vaxcyte management estimated the global conjugate pneumococcal vaccine market at about 8 to 8.5 billion dollars currently, and said it could reach 12 billion dollars or more in five to six years. Management expected the adult segment to drive market growth. On funding, the company said cash, cash equivalents and investments totaled 2.2644 billion dollars on September 30, 2026, compared with 2.4426 billion dollars on December 31, 2025, noting that the September balance does not include net proceeds from the October offering. PCVX shares closed at 59.4 dollars in the November 17, 2026 session. The company presented these figures in the context of its vaccine development plans and the size of its target market.